Using targeted next-generation sequencing, we identified a novel de novo GABRG2 missense mutation, P302L, in a patient with Dravet syndrome. Here, GABRG2 is linked to encephalopathy, progressive, early-onset, with brain edema and/or leukoencephalopathy.